Skip to main content
Bristol-Myers boosts cancer pipeline with IFM Therapeutics acquisition
8/7/2017

Bristol-Myers Squibb said it will acquire IFM Therapeutics in an effort to strengthen its cancer portfolio. BMS will make a $300 million upfront payment, while IFM investors will also benefit from additional contingent payments that could reach $1.01 billion based on the achievement of specific milestones.

Full Story: